Key result
Dipyridamole at /kg orally demonstrated antiplatelet and antithrombotic activity, with pronounced effects on platelet adhesion in vitro and primary haemostasis in animal models.
Why the study?
Does dipyridamole inhibit platelet function and thrombus formation in preclinical models?
Does dipyridamole inhibit platelet function and thrombus formation in preclinical models?
Answers are grounded in this paper and cite their sources.
Dipyridamole demonstrates antiplatelet and antithrombotic activity in preclinical in vitro and in vivo models.
SummaryIn this paper the antiplatelet and antithrombotic activity of Dipyridamole is described. In in vitro tests the effect on platelet adhesion was found to be more pronounced than that on different types of aggregation.In in vivo models a good and long lasting inhibiting effect on primary haemostasis was seen in mice. An antithrombotic effect was achieved in a thrombus formation test in rats. The dose of Dipyridamole used in these in vivo experiments was only 10mg/kg orally.
No takes yet. Share an insight, caveat, or question.
Haarman et al. (1975) studied this question. Dipyridamole was evaluated on Antiplatelet and antithrombotic activity (platelet adhesion, primary haemostasis, thrombus formation). Dipyridamole at /kg orally demonstrated antiplatelet and antithrombotic activity, with pronounced effects on platelet adhesion in vitro and primary haemostasis in animal models.
Synapse has enriched 10 related papers. Consider them for comparative context: